Cellebrite DI Ltd.
CLBT Nasdaq Services-Prepackaged Software Financials FY2019–FY2025
Cellebrite DI Ltd. had $476M of revenue in fiscal 2025, up 18.6% on the year before. Over five years, revenue changed +19.5% a year on average.
- Today
- 2.0%
- Previous close
- $12.45
- Market cap
- $3.2B
- P/E
- 41.0x
- Day range
-
$12.45 $12.84
- 52-week range
-
$10.44 $19.28
Last close · Nov 9, 2026
$12.70
−$2.70 (−17.53%) past year
Key numbers
Key numbers, fiscal 2025
Revenue and margins
Revenue and margins
KIRA summarises the numbers
-
Cellebrite DI Ltd. had $476M of revenue in fiscal 2025, up 18.6% on the year before.
Over five years, revenue changed +19.5% a year on average.
-
Its operating margin was 14.0%, down 0.2 pts: of every 100 in sales, about 14 is left after running the business.
Revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Cellebrite DI Ltd. made $78.3M of net profit in fiscal 2025.
Net income
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash flow
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was $160M in fiscal 2025, 33.7% of revenue.
Free cash flow
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Dividends, buybacks and share count
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders sold $5.4M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$5.4M
4 insiders
Of sales under plans
2%
$0.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | David BarterChief Financial Officer | Sold | 12,134 | $11.21 | $0.1M | Form 4 |
| Aug 25, 2026 | Thomas E. HoganAdvisor | Sold | 25,299 | $11.29 | $0.3M | Form 4 |
| Aug 24, 2026 | David Nicholas GeeChief Marketing Officer | Sold plan | 4,323 | $11.36 | $0.0M | Form 4 |
| Aug 21, 2026 | David Nicholas GeeChief Marketing Officer | Sold | 2,198 | $11.24 | $0.0M | Form 4 |
| Aug 21, 2026 | Marcus JewellGlobal Chief Revenue Officer | Sold | 12,562 | $11.24 | $0.1M | Form 4 |
| Aug 12, 2026 | David Nicholas GeeChief Marketing Officer | Sold | 230 | $16.07 | $0.0M | Form 4 |
| Aug 12, 2026 | Marcus JewellGlobal Chief Revenue Officer | Sold | 411 | $16.07 | $0.0M | Form 4 |
| Aug 12, 2026 | Thomas E. HoganChief Executive Officer, Director | Sold | 139,713 | $15.39 | $2.2M | Form 4 |
| Jul 8, 2026 | David BarterChief Financial Officer | Sold | 41,734 | $16.38 | $0.7M | Form 4 |
| Jul 2, 2026 | Thomas E. HoganChief Executive Officer, Director | Sold | 103,188 | $15.76 | $1.6M | Form 4 |
| May 21, 2026 | David Nicholas GeeChief Marketing Officer | Sold plan | 5,673 | $13.13 | $0.1M | Form 4 |
| May 18, 2026 | Marcus JewellGlobal Chief Revenue Officer | Sold | 12,658 | $12.77 | $0.2M | Form 4 |
| May 12, 2026 | David Nicholas GeeChief Marketing Officer | Sold | 228 | $13.01 | $0.0M | Form 4 |
| May 12, 2026 | Marcus JewellGlobal Chief Revenue Officer | Sold | 383 | $13.01 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Balance sheet
Balance sheet
Cash, debt and the ratios that show how comfortably Cellebrite DI Ltd. can carry it.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $146M | $132M | $228M | $293M | $276M |
| Current ratio | 1.5x | 1.4x | 1.7x | 1.9x | 1.6x |
| Quick ratio | 1.4x | 1.4x | 1.6x | 1.9x | 1.5x |
| Total assets | $340M | $403M | $533M | $691M | $939M |
| Total liabilities | $413M | $329M | $499M | $355M | $455M |
| Shareholders' equity | −$73.3M | $73.9M | $34.2M | $336M | $484M |
| Net debt (− = net cash) | — | — | — | — | — |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
F-score
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
KIRA summarises the numbers
-
Cellebrite DI Ltd. passes 4 of 8 financial health tests (Piotroski F-score).
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| F-score | 5 / 8 | 3 / 8 | 5 / 8 | 4 / 8 | 4 / 8 |
| Accruals ratio | 10.0% | 27.0% | −39.1% | −67.9% | −11.7% |
| Altman Z'' | 2.51 | 3.30 | 3.29 | 3.36 | 2.73 |
| Net income is positive | ✓ | ✓ | ✕ | ✕ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | ✓ | ✓ | ✕ | ✕ | ✓ |
| Cash from operations exceeds net income | ✕ | ✕ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | ✕ | ✕ | ✓ | ✓ | ✕ |
| Share count didn't rise | ✕ | ✕ | ✓ | ✕ | ✕ |
| Gross margin rose | ✓ | ✕ | ✓ | ✓ | ✕ |
| Revenue rose relative to assets | ✓ | ✕ | ✕ | ✕ | ✕ |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
7 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $172M | $195M | $246M | $271M | $325M | $401M | $476M |
| Gross profit | $136M | $157M | $204M | $220M | $272M | $339M | $401M |
| Research and development | $46.6M | $54.4M | $65.5M | $80.6M | $84.4M | $98.4M | $114M |
| Operating income | −$1.5M | $9.2M | $13.8M | $1.0M | $33.2M | $56.9M | $66.5M |
| Pretax income | $1.4M | $11.4M | $82.3M | $121M | −$75.6M | −$276M | $90.7M |
| Income tax | $3.3M | $5.6M | $10.9M | −$0.0M | $5.5M | $7.0M | $12.4M |
| Net income | −$1.9M | $5.8M | $71.4M | $121M | −$81.1M | −$283M | $78.3M |
| Net income to common | −$10.0M | −$9.3M | $70.4M | $116M | −$81.1M | −$283M | $77.8M |
| Diluted EPS | −$0.08 | −$0.08 | $0.44 | $0.59 | −$0.43 | −$1.35 | $0.31 |
| Diluted shares | 0.12B | 0.12B | 0.16B | 0.20B | 0.19B | 0.21B | 0.25B |
| Cash flow | |||||||
| Cash from operations | $16.1M | $66.5M | $36.1M | $20.6M | $102M | $132M | $174M |
| Capital expenditure | $6.2M | $6.2M | $5.1M | $6.9M | $5.2M | $8.6M | $13.2M |
| Free cash flow | $9.9M | $60.3M | $30.9M | $13.7M | $96.8M | $124M | $160M |
| Depreciation and amortization | $4.1M | $5.9M | $7.0M | $9.2M | $10.0M | $10.6M | $11.9M |
| Stock-based compensation | $12.8M | $7.3M | $6.5M | $13.7M | $19.0M | $30.6M | $44.9M |
| Acquisitions | $0.0M | $15.0M | $20.0M | $0.0M | $0.0M | $2.7M | $147M |
| Share buybacks | $0.8M | $0.1M | $0.0M | $0.0M | — | — | — |
| Dividends paid | $25.0M | $10.0M | $100M | $0.0M | $0.0M | — | — |
| Dividends and buybacks | $25.8M | $10.1M | $100M | $0.0M | $0.0M | — | — |
| Balance sheet | |||||||
| Cash and short-term investments | $81.7M | $134M | $146M | $132M | $228M | $293M | $276M |
| Current assets | — | $324M | $273M | $296M | $422M | $568M | $576M |
| Current liabilities | — | $159M | $187M | $208M | $254M | $296M | $370M |
| Inventory | — | $4.8M | $6.5M | $10.2M | $9.9M | $8.9M | $7.6M |
| Property and equipment, net | — | $16.1M | $16.8M | $17.3M | $15.9M | $17.0M | $22.2M |
| Goodwill | — | $9.5M | $26.8M | $26.8M | $26.8M | $28.7M | $120M |
| Intangible assets | — | $6.6M | $11.2M | $11.3M | $10.6M | $11.3M | $81.5M |
| Total assets | — | $364M | $340M | $403M | $533M | $691M | $939M |
| Total liabilities | — | $199M | $413M | $329M | $499M | $355M | $455M |
| Shareholders' equity | $58.8M | $63.8M | −$73.3M | $73.9M | $34.2M | $336M | $484M |
| Margins | |||||||
| Gross margin | 79.2% | 80.6% | 82.7% | 81.3% | 83.6% | 84.4% | 84.2% |
| Operating margin | −0.9% | 4.7% | 5.6% | 0.4% | 10.2% | 14.2% | 14.0% |
| EBITDA margin | 1.5% | 7.7% | 8.5% | 3.8% | 13.3% | 16.8% | 16.5% |
| Net margin | −1.1% | 3.0% | 29.0% | 44.6% | −24.9% | −70.5% | 16.5% |
| FCF margin | 5.8% | 31.0% | 12.6% | 5.1% | 29.8% | 30.8% | 33.7% |
| Returns | |||||||
| Return on capital employed | — | 4.5% | 9.0% | 0.5% | 11.9% | 14.4% | 11.7% |
| Return on equity | −3.2% | 9.4% | — | 46,642.9% | −150.1% | −152.9% | 19.1% |
| Return on assets | — | 1.6% | 20.3% | 32.5% | −17.3% | −46.3% | 9.6% |
| Return on tangible equity | −17.1% | −19.6% | — | 324.5% | — | −95.6% | 27.5% |
| Growth | |||||||
| Revenue growth | — | 13.4% | 26.3% | 9.9% | 20.1% | 23.4% | 18.6% |
| Net income growth | — | — | 1,135.0% | 69.2% | −167.1% | — | — |
| EPS growth | — | — | — | 34.1% | −172.9% | — | — |
| FCF growth | — | 507.9% | −48.7% | −55.8% | 607.8% | 27.7% | 29.7% |
| Share count change | — | 1.8% | 30.6% | 21.0% | −2.7% | 10.2% | 19.3% |
| Financial health | |||||||
| Current ratio | — | 2.0x | 1.5x | 1.4x | 1.7x | 1.9x | 1.6x |
| Quick ratio | — | 2.0x | 1.4x | 1.4x | 1.6x | 1.9x | 1.5x |
| Capital allocation | |||||||
| Capex / revenue | 3.6% | 3.2% | 2.1% | 2.5% | 1.6% | 2.1% | 2.8% |
| Stock comp / revenue | 7.4% | 3.7% | 2.6% | 5.1% | 5.8% | 7.6% | 9.4% |
| Payouts / FCF | 260.1% | 16.7% | 323.2% | 0.0% | 0.0% | — | — |
| Quality scores | |||||||
| Piotroski F-score | — | — | 5.0 | 3.0 | 5.0 | 4.0 | 4.0 |
| Altman Z'' | — | 3.7 | 2.5 | 3.3 | 3.3 | 3.4 | 2.7 |
| Accruals ratio | — | −16.7% | 10.0% | 27.0% | −39.1% | −67.9% | −11.7% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
News and filings
Latest SEC filings
The original documents every number on this page comes from.
KIRA analysis
KIRA’s summary AI analyst
Hi! I read Cellebrite DI Ltd.’s latest annual report (fiscal 2025). Here is what stands out:
Cellebrite DI Ltd. in 30 seconds
Good So-so Weak
Are sales growing?
+18.6%
Yes. Sales grew 18.6% last year.
Does it make a profit?
16.5%
Yes. It keeps 16.5% of every sale as profit.
Does profit turn into cash?
33.7%
Yes. 33.7% of sales ends up as free cash.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
41.0x
One share costs 41.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Sales and profit
2 1 3 notes
- Cellebrite DI Ltd. had $476M of revenue in fiscal 2025, up 18.6% on the year before. Over five years, revenue changed +19.5% a year on average.
- Its operating margin was 14.0%, down 0.2 pts: of every 100 in sales, about 14 is left after running the business.
- Cellebrite DI Ltd. made $78.3M of net profit in fiscal 2025.
Cash and shareholders
1 2 notes
- Free cash flow was $160M in fiscal 2025, 33.7% of revenue.
- In the last 12 months, insiders sold $5.4M of shares on the open market and bought none.
Financial health
1 note
- Cellebrite DI Ltd. passes 4 of 8 financial health tests (Piotroski F-score).
Source: SEC EDGAR XBRL filings (CIK 0001854587). Data updated November 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.